Literature DB >> 26499190

ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target.

Xudong Zhang1, Lu Zhao2, Xin Li1, Xinhua Wang1, Ling Li1, Xiaorui Fu1, Zhenchang Sun1, Zhaoming Li1, Feifei Nan1, Yu Chang1, Mingzhi Zhang3.   

Abstract

Nasal-type natural killer/T-cell (NK/T-cell) lymphomas are subtypes of non-Hodgkin's lymphoma (NHL), which are typically more clinically aggressive. There is, however relatively little understanding of nasal-type NK/T-cell lymphoma molecular pathogenesis. Thus, in this study we applied RNA sequencing to systematically screen for altered gene expression in human NK/T-cell lymphoma cell lines YTS and SNK-6 versus normal NK cells. We found that ATP-binding cassette sub-family C Member 4 (ABCC4) levels were significantly upregulated both in human NK/T-cell lymphoma YTS and SNK-6 cells, as compared with normal NK cells. These expression levels were further confirmed by real-time PCR. Protein levels of ABCC4 were also significantly higher in YTS and SNK-6 cells as compared with normal NK cells. Clinically relevant, ABCC4 expression levels were significantly higher in human NK/T-cell lymphoma tissues as compared with control nasal mucosa tissues, confirmed by immunohistochemical staining. In addition, we explored the biological function of such ABCC4 upregulation. Overexpression of ABCC4 by lentivirus transfection induced chemotherapy resistance to epirubicin (EPI) and cisplatin (DDP) in YTS cells. In contrast, knockdown of ABCC4 expression by shRNA contributed to chemotherapy sensitivity by both EPI and DDP. Furthermore, overexpression of ABCC4 inhibited, while downregulation of ABCC4 increased, YTS cell apoptosis following treatment by EPI or DDP. Therefore, the present study identified ABCC4 to be overexpressed in human NK/T-cell lymphoma cells, to regulate chemotherapy sensitivity to EPI and DDP, and possibly to be a functional therapeutic target. These findings may provide a basic rationale for new approaches in the effort to develop anti-tumor therapeutics for NK/T-cell lymphoma.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ABCC4; Cisplatin; Epirubicin; NK/T-cell lymphoma

Mesh:

Substances:

Year:  2015        PMID: 26499190     DOI: 10.1016/j.leukres.2015.10.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway.

Authors:  Yuan Mao; Jun Wang; Mingzhi Zhang; Weifei Fan; Qi Tang; Siping Xiong; Xiaojun Tang; Juqing Xu; Lin Wang; Shu Yang; Suyao Liu; Li Xu; Yan Chen; Lin Xu; Rong Yin; Jin Zhu
Journal:  Oncotarget       Date:  2017-02-14

2.  Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type.

Authors:  Ya-Jun Li; Ping-Yong Yi; Ji-Wei Li; Xian-Ling Liu; Xi-Yu Liu; Fang Zhou; Zhou OuYang; Zhong-Yi Sun; Li-Jun Huang; Jun-Qiao He; Yuan Yao; Zhou Fan; Tian Tang; Wen-Qi Jiang
Journal:  Oncotarget       Date:  2017-01-17

Review 3.  T-cell lymphomas, a challenging disease: types, treatments, and future.

Authors:  Helen Ma; Maher Abdul-Hay
Journal:  Int J Clin Oncol       Date:  2016-10-14       Impact factor: 3.402

4.  Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy.

Authors:  Henry Döring; David Kreutzer; Christoph Ritter; Andreas Hilgeroth
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

Review 5.  The RNA m6A writer WTAP in diseases: structure, roles, and mechanisms.

Authors:  Qibo Huang; Jie Mo; Zhibin Liao; Xiaoping Chen; Bixiang Zhang
Journal:  Cell Death Dis       Date:  2022-10-07       Impact factor: 9.685

6.  Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?

Authors:  Xudong Zhang; Xiaorui Fu; Meng Dong; Zhenzhen Yang; Shaoxuan Wu; Mijing Ma; Zhaoming Li; Xinhua Wang; Ling Li; Xin Li; Zhenchang Sun; Yu Chang; Feifei Nan; Jiaqin Yan; Yun Mao; Mingzhi Zhang; Qingjiang Chen
Journal:  Cancer Cell Int       Date:  2018-10-01       Impact factor: 5.722

7.  IL-13 Contributes to Drug Resistance of NK/T-Cell Lymphoma Cells by Regulating ABCC4.

Authors:  Mingli Ni; Beibei Qin; Ling Xie; Xudong Zhang; Jiezhi Yang; Hongqiong Lv; Mingyue Yang; Mingzhi Zhang
Journal:  Biomed Res Int       Date:  2018-12-13       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.